NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2020
Christopher Parks · INTERNATIONAL AIDS VACCINE INITIATIVE · 2020 · $14,125 — PROJECT SUMMARY The overall goal of this project is to develop and compare three new HIV envelope (Env) trimer delivery vaccines that are designed to mimic the natural presentation of the transmembrane glycoprotein complex (the spike) that occurs during HIV infection. Our vaccine design approach …
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2020
JOHN H. SAMPSON · DUKE UNIVERSITY · 2020 · $691,384 — PROJECT SUMMARY – Project 1 We recently reported in Nature that patients with glioblastoma (GBM) randomized to receive a vaccine against Cytomegalovirus (CMV) major integument protein pp65 using a tetanus/diphtheria (Td) vaccine site preconditioning regimen had a statistically significant increase i…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2020
CATHERINE MARY O'CONNELL · UNIV OF NORTH CAROLINA CHAPEL HILL · 2020 · $165,241 — In a subset of Chlamydia trachomatis-infected women, the infection escapes immune control and ascends to the upper reproductive tract. There is a fundamental gap in understanding how pathways activated by chlamydial infection lead to immune pathology and reproductive morbidity in women. Its continue…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2020
Barton F. Haynes · DUKE UNIVERSITY · 2020 · $277,719 — The Administrative Core will coordinate the scientific and administrative activities of this IPCAVD Program, ensuring that the Projects and Cores function well together. In particular, it will be responsible for managing the program's financial management, program management, and coordinating Projec…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2020
Thomas Denny · DUKE UNIVERSITY · 2020 · $1,949,407 — HIV vaccine candidates entering into clinical testing generally fall into three categories: 1) recombinant envelope (Env) protein immunogens, 2) viral vectors, and 3) plasmid DNA. Numerous vaccine Env designs are being tested in clinical trials. Likewise, numerous HIV vaccine inserts, such as mosaic…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2020
THOMAS F GAJEWSKI · UNIVERSITY OF CHICAGO · 2020 · $221,729 — ABSTRACT The main purpose of the Human Immunologic Monitoring and Current Good Manufacturing Practice (HIM- cGMP) Facility is to provide support to investigators at the University of Chicago Medicine Comprehensive Cancer Center (UCCCC) who conduct immunotherapy clinical trials through preparing vacc…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2020
Barton F. Haynes · DUKE UNIVERSITY · 2020 · $3,194,965 — Administrative Core The IPCAVD Administrative Core will serve to coordinate all scientific and administrative activities of the Duke IPCAVD, ensuring that the Projects and Cores function well together. A primary activity of the Core will be monitoring IPCAVD progress relative to milestones and measu…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2020
Sallie R. Permar · DUKE UNIVERSITY · 2020 · $354,930 — ABSTRACT – Nonhuman Primate Core (NHP Core/ Core 1) The end of the HIV/AIDS epidemic will be achievable only when an effective vaccine regimen can achieve long-term protective immunity, similar to that of vaccines that have nearly eliminated other global pathogens. HIV acquisition risk begins in ute…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2020
CHRISTOPHER P. HILL · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · 2020 · $311,488 — ABSTRACT The success of antiretroviral therapy (ART) has transformed the HIV/AIDS pandemic into a life-long chronic disease, yet major challenges remain as a growing population of ~35 million patients living with HIV continues to face significant health challenges. These include side-effects and tox…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2020
THOMAS F GAJEWSKI · UNIVERSITY OF CHICAGO · 2020 · $4,735 — ABSTRACT The main purpose of the Human Immunologic Monitoring and Current Good Manufacturing Practice (HIM- cGMP) Facility is to provide support to investigators at the University of Chicago Medicine Comprehensive Cancer Center (UCCCC) who conduct immunotherapy clinical trials through preparing vacc…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2020
GARY FUJII · MOLECULAR EXPRESS, INC. · 2020 · $299,993 — Particle-Based Co-Delivery of HIV Immunogens as Next-Generation HIV Vaccines: A major focus of HIV vaccine research has been the development of immunogens that elicit broadly neutralizing antibody responses targeting the envelope protein (Env). While the field has predominantly focused on immunogen …
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2020
Laimonis A. LAIMINS · NORTHWESTERN UNIVERSITY AT CHICAGO · 2020 · $355,500 — PROJECT SUMMARY Human papillomaviruses (HPV) are the causative agents of cervical, anal and many oral cancers. While prophylactic vaccines to prevent HPV infections have been developed, there is no effective therapeutic treatment for existing HPV lesions. It is therefore of critical importance to un…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2020
Julie Magarian Blander · WEILL MEDICAL COLL OF CORNELL UNIV · 2020 · $419,267 — PROPOSAL SUMMARY Live attenuated vaccines have proven to be the most efficient human vaccines for many serious infectious diseases. When compared to their dead counterparts, live vaccines induce superior immune protection and lasting memory. But despite the efficacy of live vaccines, concerns over t…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2020
Ranjit Ray · SAINT LOUIS UNIVERSITY · 2020 · $340,875 — Abstract Chronic hepatitis C virus (HCV) infection often causes end stage liver disease. Although current anti-HCV drugs are successful in eliminating viral RNA load, they do not prevent reinfection. In addition, eliminating HCV RNA load does not reduce the risk for progression to end stage liver di…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2020
Wen Jiang · UT SOUTHWESTERN MEDICAL CENTER · 2020 · $253,377 — Project Summary Despite significant advances in the treatment of breast cancer, the metastatic form of the disease remains highly lethal, with a 5-year overall survival rate of only around 20%. Even with the use of new, targeted therapies such as antibodies against the human epidermal receptor 2 (H…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2020
John T Chang · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2020 · $557,572 — Project Summary Mortality from infectious diseases remains a leading cause of death worldwide, making the development of new vaccines an important priority of biomedical research. Immunologic memory is a cardinal feature of adaptive immunity and an important goal of vaccination strategies. Traditio…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2020
Isaac Jonathan Krauss · BRANDEIS UNIVERSITY · 2020 · $587,087 — Project Summary/Abstract Extensive study of HIV+ individuals in recent years has brought to light many examples of antibodies that can neutralize a broad range of HIV strains and protect against viral challenge in animal models of infection. The portion of viral surface most commonly targeted by suc…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2020
Asok Antony · RLR VA MEDICAL CENTER · 2020 — Despite the advent of effective anti-Human Papillomavirus (HPV) vaccines, there are no biological agents to reliably prevent ~80 million Americans from transmitting their infectious HPV viral particles to sexual partners. Earlier we determined that the post-translational homocysteinylation of an mR…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2020
Kristina De Paris · DUKE UNIVERSITY · 2020 · $1,307,799 — ABSTRACT – Overall Nearly 600,000 new HIV infections occur yearly in adolescents/young adults (ages 15-24 years), the only population in which HIV infections continue to rise. The end of the HIV/AIDS epidemic will be achievable only when an effective vaccine regimen can elicit long-term protective i…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2020
Scott G Hansen · OREGON HEALTH & SCIENCE UNIVERSITY · 2020 · $1,146,291 — Project Summary With 36 million people currently living with HIV worldwide, developing a prophylactic HIV vaccine that protects against sexual transmission remains a top global health priority. A pre-clinical HIV vaccine approach based on strain 68-1 of rhesus cytomegalovirus expressing SIV antigens…